CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis
Author:
Publisher
Elsevier BV
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference55 articles.
1. Counterpoint: adjuvant therapy in stage II colon cancer: pain not justified by the gain;Van Loon;J Natl Compr Canc Netw,2012
2. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features;O’Connor;J Clin Oncol,2011
3. Ongoing challenge of stage II colon cancer;Meropol;J Clin Oncol,2011
4. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer;Benson;J Clin Oncol,2004
5. CDX2 as a prognostic biomarker in Stage II and Stage III colon cancer;Dalerba;N Engl J Med,2016
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of Adipose-Derived Stem Cell Microenvironment on Colon Cancer Progression;J BIOL REG HOMEOS AG;2024
2. Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?;PharmacoEconomics;2024-04-07
3. Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer;Pathology and Oncology Research;2023-05-31
4. Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review;Cost Effectiveness and Resource Allocation;2023-01-31
5. CDX2 testing + FOLFOX for CDX2-negative colon cancer patients cost-effective strategy;PharmacoEconomics & Outcomes News;2021-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3